CA2730804A1 - Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses - Google Patents

Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses Download PDF

Info

Publication number
CA2730804A1
CA2730804A1 CA2730804A CA2730804A CA2730804A1 CA 2730804 A1 CA2730804 A1 CA 2730804A1 CA 2730804 A CA2730804 A CA 2730804A CA 2730804 A CA2730804 A CA 2730804A CA 2730804 A1 CA2730804 A1 CA 2730804A1
Authority
CA
Canada
Prior art keywords
amino acid
acid residue
sequence
amyloid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2730804A
Other languages
English (en)
French (fr)
Inventor
Stefan Barghorn
Heinz Hillen
Rohinton Edalji
Leo Barrett
Paul Richardson
Liping Yu
Edward Olejniczak
John Harlan
Thomas Holzman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Original Assignee
Abbott GmbH and Co KG
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG, Abbott Laboratories filed Critical Abbott GmbH and Co KG
Publication of CA2730804A1 publication Critical patent/CA2730804A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2730804A 2008-07-25 2009-07-24 Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses Abandoned CA2730804A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8358908P 2008-07-25 2008-07-25
US61/083,589 2008-07-25
PCT/US2009/051721 WO2010011947A2 (en) 2008-07-25 2009-07-24 AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES

Publications (1)

Publication Number Publication Date
CA2730804A1 true CA2730804A1 (en) 2010-01-28

Family

ID=41570887

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2730804A Abandoned CA2730804A1 (en) 2008-07-25 2009-07-24 Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses

Country Status (7)

Country Link
US (1) US20110092445A1 (https=)
EP (1) EP2303920A4 (https=)
JP (1) JP2011529084A (https=)
CN (1) CN102203124A (https=)
CA (1) CA2730804A1 (https=)
MX (1) MX2011000975A (https=)
WO (1) WO2010011947A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US9688734B2 (en) 2008-04-14 2017-06-27 Alzinova Ab Stable amyloid beta monomers and oligomers
US9045555B2 (en) * 2008-07-01 2015-06-02 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
AU2013205000B2 (en) * 2010-03-03 2015-05-28 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
RU2644335C2 (ru) * 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011156003A2 (en) 2010-06-09 2011-12-15 New York University Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US20120089291A1 (en) * 2010-10-12 2012-04-12 Halder Bibhrajit Autonomous machine control system
PL2646462T3 (pl) 2010-11-29 2017-10-31 Akershus Univ Sposoby i kompozycje do monitorowania aktywności fagocytarnej
WO2012072611A1 (de) * 2010-11-29 2012-06-07 Philipps-Universität Marburg SYNTHETISCHE LIGANDEN FÜR HUMANE ANTI-Aβ-ANTIKÖRPER
CN114748605A (zh) * 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
US20130164217A1 (en) * 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
DE102012021222B4 (de) * 2012-10-27 2015-02-05 Forschungszentrum Jülich GmbH Verfahren zur Herstellung einer nanoporösen Schicht auf einem Substrat
EP2746402A1 (en) * 2013-03-12 2014-06-25 Academisch Medisch Centrum Method of prognosis of Alzheimers disease and substrates for use therein
EP2787349A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
EP2787347A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
RU2750268C2 (ru) * 2014-07-07 2021-06-25 Эббви Дойчланд Гмбх Унд Ко. Кг ИММУНОГЕННЫЕ ПРОДУКТЫ, ПОЛУЧЕННЫЕ НА ОСНОВЕ АМИНОКИСЛОТНЫХ ПОСЛЕДОВАТЕЛЬНОСТЕЙ МУТЕИНОВОГО АМИЛОИДА β (Aβ), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2016037036A2 (en) * 2014-09-05 2016-03-10 System Of Systems Analytics, Inc. Methods for detecting amyloid beta oligomers
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
WO2018005980A1 (en) * 2016-07-01 2018-01-04 The Scripps Research Institute Compositions and diagnostic methods related to transthyretin amyloid diseases
EP3634394B1 (en) 2017-05-15 2025-12-24 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN108148115A (zh) * 2018-01-30 2018-06-12 中国药科大学 一种环肽合成新方法及其在药物开发中的应用
WO2019246140A1 (en) * 2018-06-18 2019-12-26 Emory University Parallel enzyme digestion for protein biomarker detection
CN109851660A (zh) * 2019-03-20 2019-06-07 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽及其疫苗
CN109912687A (zh) * 2019-03-20 2019-06-21 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽药物
JP7357354B2 (ja) * 2020-02-04 2023-10-06 国立大学法人京都大学 アミロイドβ４２架橋アナログペプチド
KR102767892B1 (ko) * 2021-12-30 2025-02-14 고려대학교 산학협력단 신규한 단백질 변이체 및 이를 이용한 신경퇴행성 질환 치료용 조성물
US12037375B2 (en) * 2021-12-30 2024-07-16 Korea University Research And Business Foundation Protein variant and composition for treating neurodegenerative disease using the same
WO2026030341A1 (en) 2024-07-29 2026-02-05 Cognition Therapeutics, Inc. Zervimesine for treating neurodegenerative disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0683234B2 (en) * 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
US20020132758A1 (en) * 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
US20070213512A1 (en) * 2002-10-01 2007-09-13 Krafft Grant A Amyloid beta peptide analogs and assemblies thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
WO2006094724A2 (en) * 2005-03-05 2006-09-14 Abbott Gmbh & Co. Kg Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
US8263558B2 (en) * 2005-11-30 2012-09-11 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
US9126987B2 (en) * 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase

Also Published As

Publication number Publication date
MX2011000975A (es) 2011-05-25
CN102203124A (zh) 2011-09-28
WO2010011947A2 (en) 2010-01-28
EP2303920A4 (en) 2011-11-09
JP2011529084A (ja) 2011-12-01
WO2010011947A3 (en) 2010-04-29
EP2303920A2 (en) 2011-04-06
US20110092445A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
CA2730804A1 (en) Amyloid .beta. peptide analogues, oligomers thereof, processes for preparing and compositions comprising said analogues or oligomers, and their uses
US20240075114A1 (en) IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
CN102459333B (zh) 抗-Tau pS422抗体用于治疗脑病的应用
CA2791538C (en) Oligomer-specific amyloid beta epitope and antibodies
JP2000516572A (ja) プリオンタンパク質に結合し、イソ型ＰｒＰ▲上ｃ▼とＰｒＰ▲上ｓｃ▼を識別することが可能なシャペロン
WO2010010469A2 (en) Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
AU2021203496A1 (en) Super versatile method for presenting cyclic peptide motif on protein structure
US11319348B2 (en) Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
JP4079775B2 (ja) β−アミロイドペプチドの可溶性環状類似体
Ball et al. Engineering the prion protein using chemical synthesis
AU2003288434B2 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
US20090099343A1 (en) Isolation of pathogenic prions
WO2004018511A2 (en) Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20250115638A1 (en) Peptide antigens for formylmethionine antibody production
WO2014014819A2 (en) Methods of treating glucose metabolism disorders
WO2013151627A1 (en) Methods of treating glucose metabolism disorders
BR112017000428B1 (pt) Produto imunogênico com base em sequências de aminoácidos muteína amiloide beta, composição compreendendo o produto e uso do mesmo para tratar ou prevenir amiloidose
WO2014014816A2 (en) Methods of treating glucose metabolism disorders

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150724